TERT and lung cancer: HLA-DR restricted peptides were also more useful at assessing pre-existing anti-TERT immunity in individual patients since the percentage of lung cancer patients responding to HLA-DR restricted peptides was greater than that of patients responding to HLA-DP (25% vs 10%, respectively) [107].